Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320058 · ClinicalTrials.gov registry record · Phase 2
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
A Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
- 20
- Study locations
NCT02320058 is a Phase 2 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 119 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT02320058, a Phase 2 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study of Nivolumab combined with Ipilimumab followed by Nivolumab by itself for the treatment of patients with Melanoma that has spread to the brain. Patients with histologically confirmed Malignant Melanoma and asymptomatic brain metastases are eligible for the study.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (20)
California
- City of Hope - Duarte
- Angeles Clinic and Research Institute - Los Angeles
- UCLA Medical Hematology and Oncology - Los Angeles
- Stanford University - Palo Alto
- The California Pacific Medical Research Institute - San Francisco
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
District of Columbia
- Washington Cancer Inst at MedStar Washington Hospital Ctr - Washington D.C.
- Weinberg Cancer Institute At Franklin Square - Washington D.C.
- Georgetown University Medical Center - Washington D.C.
Florida
- Mount Sinai Medical Center - Miami Beach
- H Lee Moffitt Cancer Center and Research Institute - Tampa
- The Cleveland Clinic Foundation - Weston
Massachusetts
- Dana Farber Cancer Institute. - Boston
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Illinois
- University of Chicago - Chicago
- Loyola University Medical Center - Maywood
Colorado
- University of Colorado - Cancer Center - PPDS - Aurora
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2015-03-05 |
| Est. Completion | 2020-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02320058
The ClinicalTrials.gov registry entry for NCT02320058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (83% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02320058 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT02320058 about?
NCT02320058 is a clinical study titled "An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself". This is a study of Nivolumab combined with Ipilimumab followed by Nivolumab by itself for the treatment of patients with Melanoma that has spread to the brain. Patients with histologically confirmed Malignant Melanoma and asymptomatic brain metastases are eligible for the study.
What is the current status of trial NCT02320058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2015-03-05. Estimated completion is 2020-09-08.
What conditions does trial NCT02320058 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02320058?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02320058?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02320058 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.